Show results for
Refine by
Industries served
Disease Target Suppliers Serving Morocco
62 companies found
based inAmes, ALABAMA (USA)
Mazen Animal Health harnesses the power of plant biotechnology to create orally delivered biologics, aimed at significantly improving animal health and welfare. The company's innovative cross-species platform is versatile enough to target various ...
The platform's efficacy is driven by a methodical process including protein design, where subunit antigens are selected to target diseases effectively, followed by the insertion of these genes into the corn genome ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Peptides are an increasingly important class of drug. As natural ligands to many targets, they can combine agonistic or antagonistic activity with low toxicity risk and can be applied to disease ...
based inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
AdAlta is utilising the power of the i-body technology platform to develop a growing pipeline of i-bodies to treat a range of conditions, with an initial focus on treating fibrotic diseases. AdAlta identified an i-body that binds to ...
based inNotting Hill, AUSTRALIA
INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases to improve patient outcomes ...
INOVIQ’s NETs technology is a sample preparation platform with the potential to revolutionise the performance of liquid biopsy diagnostic assays. The market potential for liquid biopsy applications is estimated at billions of dollars ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be ...
based inEschborn, GERMANY
When we looked at the decision making landscape in organizations and observed that the available technologies and models were helping make decisions but with fixed cycles of information processing, running in batches, with little flexibility and ...
Ontosight Explore enables the exploration, detection and building of various direct and in-direct connections between drug, target, pathway and disease. We leverage a biological network model using enhanced natural ...
based inOxford, UNITED KINGDOM
Founded in 2012, we are the leading pharmatech company and the first to automate drug discovery. As a full stack AI drug discovery company, we generate our own data before combining the analytical power of AI with the creativity and expertise of our ...
Target selection is key to creating success in drug discovery. Selecting each target is a significant decision and the future success of any molecule will depend on that initial ...
based inBasel, SWITZERLAND
EsoCap’s vision is to improve the lives of patients affected by esophageal diseases. The esophagus is a particularly challenging environment, as swallowed drugs only remain in the area between the mouth and the stomach for a few seconds. EsoCap, a ...
based inAbercynon, UNITED KINGDOM
Imspex provides cutting-edge analytics solutions where early warning signals are needed. Our versatile combination of gas chromatography (GC) and ion mobility spectrometry (IMS) has already proven itself in medical detection and medical diagnosis ...
based inRostock, GERMANY
Since 2006, CENTOGENE has helped physicians diagnose thousands of rare disease patients around the world. A quick and accurate diagnosis can end an odyssey of medical tests and visits to multiple medical specialists. It also helps physicians better ...
We work with partners to develop new disease models and new biomarkers of disease. We can also use our disease models to identify new drug targets and screen chemical compounds to ...
based inCambridge, MASSACHUSETTS (USA)
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. ...
At Moderna, we are delivering on the promise of mRNA science to create a new generation of transformative medicines for ...
based inDreieich, GERMANY
Biotest - innovation in haematology, clinical immunology and intensive care medicine. Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine. Biotest develops, manufactures and markets plasma proteins and ...
based inIselin, NEW JERSEY (USA)
Excelra (formally Excelra Knowledge Solutions), established in 2016, is a dynamic informatics company focused on accelerating drug discovery and development through advanced data analytics and integrative informatics services. The organization ...
As the volume of biomedical data increases, so does the complexity of drug discovery and development programs. There’s a wealth of opportunity out there but capturing high-quality data and putting it to immediate productive use is often ...
based inWellesley Heights, MASSACHUSETTS (USA)
Novel point-of-care diagnostics for earlier disease detection. SANO Diagnostics is developing a range of disposable, cost-effective point-of-care diagnostics to detect the early onset of inflammation in several disease states. We are a development ...
based inAbingdon, UNITED KINGDOM
Thermally Stable Needle Free Solid Dose Vaccines. Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax technologies. These diseases affect millions of ...
based inHuesca, SPAIN
Vitassay develops and distributes reliable and certified solutions for the early detection of different pathogens which cause infectious diseases in humans. Our greatest asset is to offer a complete service for every customer to exceed their ...
based inLexington, MASSACHUSETTS (USA)
Fractyl Health is an organ editing metabolic therapeutics company focused on pioneering a new approach to the treatment of Type 2 Diabetes (T2D). Our goal is to transform T2D treatment from chronic blood glucose management to disease-modifying ...
based inLondon, UNITED KINGDOM
At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment. Building the right team is an art not a science. We strive ...
The Benevolent Platform™ is our powerful computational R&D platform. At its core sits our Knowledge Graph, which captures the interconnectivity of all relevant available data and scientific literature. Our suite of ...
based inTokyo, JAPAN
At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early ...
based inNew York City, NEW YORK (USA)
At Kallyope, we are pioneering the science and understanding of gut and gut-brain biology to create medicines that transform human health. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top ...
At Kallyope, we are pioneering the science and understanding of gut and gut-brain biology to create medicines that transform human ...